-

International Microphysiological Systems Society formally established at MPS World Summit, 2023

BERLIN--(BUSINESS WIRE)--The International Microphysiological Systems Society (IMPSS) was officially established during the second MPS World Summit in Berlin, Germany on June 30, 2023. The conference brought together stakeholders from funding agencies, regulators, commercial developers, and end-users to discuss the latest developments and the future of human-based drug discovery tools. The attendance tripled from the previous year, indicating the growing interest and excitement in this field, with close to 1300 attendees and 96 sponsors, and the meeting next year is expected to continue this trend.

At the closing ceremony, the governing board was established, and the official bylaws were approved. The board comprises 19 individuals from different regions globally, recognized as leaders in their respective fields. The organization's mission is to connect, exchange, and educate, specifically to connect technology developers, funding agencies, and industries; exchange knowledge of the latest advancements within the community to accelerate progress; and educate both the public and next generation of leaders in the field.

The governing board is led by Lena Smirnova of Johns Hopkins as the founding President, James Hickman of Hesperos, Inc. as President-elect, Jan Lichtenberg of Insphero as Secretary, and Riccardo Barrile of University of Cincinnati as Treasurer.

Moving forward, the organization will oversee the coordination of the annual MPS World Summit, where the next meeting will be in Seattle, WA from June 10-14, 2024. It will also distribute the latest information as the technology and regulatory landscape develops and advocate for the adoption and utilization of MPS systems.

To learn more about IMPSS and its membership benefits, visit their website at impss.org.

Contacts

For media inquiries, contact Anwyn Statnick at info@impss.org.

Industry:

Hesperos, Inc.

Release Versions
English
Hashtags
#biotech
#drugdiscovery
#leadership
#organonachip

Contacts

For media inquiries, contact Anwyn Statnick at info@impss.org.

Social Media Profiles
LinkedIn
Twitter
More News From Hesperos, Inc.

Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive Dysfunction

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform, is pleased to announce the publication of a new peer-reviewed study, developed in collaboration with Bayer Consumer Health. The study introduces the first human-relevant microphysiological system (MPS) capable of modeling central nervous system (CNS) stress res...

Hesperos Demonstrates First Digital Twin of Human Disease Using Organ-on-a-Chip Platform

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos creates first organ-on-a-chip digital twin to predict drug responses, setting a new benchmark for New Approach Methodologies (NAMs)...

Hesperos Wins ACC.25 Pitch Competition as FDA Unveils Plan to Move Beyond Animal Testing

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos wins ACC.25 Pitch, showcasing how its Human-on-a-Chip® is accelerating drug development and reducing reliance on animal testing....
Back to Newsroom